test
efficaci
coronaviruslik
particl
vlp
protect
mice
sever
acut
respiratori
syndrom
coronaviru
scov
infect
coexpress
scov
protein
e
n
protein
mous
hepat
viru
cho
cell
result
effici
product
chimer
vlp
carri
scov
protein
balbc
mice
inocul
mixtur
chimer
vlp
alum
twice
interv
four
week
protect
scov
challeng
indic
absenc
infecti
viru
lung
group
mice
high
level
scovspecif
neutral
antibodi
mice
neg
control
group
immun
chimer
vlp
fail
manifest
neutral
antibodi
suggest
scovspecif
neutral
antibodi
import
suppress
viral
replic
within
lung
despit
differ
cellular
composit
inflammatori
infiltr
observ
overt
lung
patholog
chimericvlptr
mice
compar
neg
control
mice
result
show
chimer
vlp
effect
vaccin
strategi
scov
infect
sever
acut
respiratori
syndrom
sar
newli
emerg
diseas
caus
sar
coronaviru
scov
sar
origin
southern
china
spread
five
differ
contin
caus
infect
death
appar
erad
human
infect
healthcar
system
affect
area
sever
stress
addit
econom
cost
trade
travel
high
known
viru
reintroduc
human
popul
ancestr
coronavirus
wide
distribut
bat
thought
adapt
civet
human
recent
time
period
emerg
virus
tend
reemerg
condit
chang
highli
desir
develop
safe
efficaci
vaccin
andor
antivir
prevent
scov
infect
correspond
shinji
makino
kgl
nyi
contribut
equal
studi
coronavirus
includ
scov
carri
four
structur
protein
nucleocapsid
n
protein
three
envelop
protein
name
spike
protein
type
transmembran
glycoprotein
envelop
e
protein
membran
protein
three
membranespan
domain
coronaviru
protein
respons
viru
adsorpt
suscept
cell
specif
virusreceptor
interact
induc
membran
fusion
viral
envelop
host
cell
membran
protein
main
player
determin
coronaviru
tissu
tropism
host
specif
viral
pathogen
coronaviru
neutral
antibodi
recogn
protein
surpris
current
scov
vaccin
candid
either
protein
subunit
carri
protein
furthermor
prophylact
administr
monoclon
antibodi
direct
scov
protein
protect
anim
subsequ
scov
challeng
studi
point
neutral
antibodi
recogn
scov
protein
suffici
prevent
decreas
morbid
mortal
associ
scov
infect
primarili
suppress
replic
challeng
viru
coronaviruslik
particl
vlp
produc
cell
coexpress
e
protein
express
latter
two
protein
suffici
vlp
product
protein
play
central
role
viru
assembl
protein
assembl
coronaviru
particl
proteinm
protein
interact
interact
protein
rna
packag
signal
viral
rna
n
protein
drive
incorpor
helic
nucleocapsid
complex
consist
viral
genom
n
protein
viru
particl
vaccinia
viru
andor
alphaviru
replicon
use
express
coronaviru
protein
enabl
gener
vlp
report
product
scov
vlp
cell
cotransfect
four
eukaryot
pcaggsbas
express
plasmid
encod
scov
n
e
protein
other
also
report
product
scov
vlp
insect
cell
mammalian
cell
studi
coronaviru
assembl
found
effici
product
chimer
vlp
carri
scov
protein
murin
coronaviru
mous
hepat
viru
mhv
n
e
protein
cell
coexpress
protein
mice
immun
chimer
vlp
present
studi
describ
elicit
antibodi
neutral
scov
suppress
challeng
scov
replic
lung
find
suggest
use
chimer
vlp
effect
vaccin
strategi
scov
infect
vero
cell
cell
cho
cell
grown
dulbecco
modifi
minimum
essenti
medium
dmem
supplement
penicillin
unitsml
streptomycin
sodium
bicarbon
fetal
bovin
serum
fb
urbani
strain
scov
obtain
tg
ksiazek
center
diseas
control
prevent
atlanta
ga
work
stock
viru
prepar
serial
passag
portion
seed
viru
twice
vero
cell
cultur
fluid
infect
cell
clarifi
lowspe
centrifug
filter
use
filter
portion
frozen
medium
uninfect
vero
cell
similarli
treat
process
plasmid
construct
insert
entir
region
mhv
structur
protein
e
n
respect
chicken
betaactin
promoterbas
express
plasmid
pcaggsmc
plasmid
obtain
paul
master
use
templat
pcr
amplif
mhv
structur
gene
construct
plasmid
pcaggss
express
scov
protein
pcaggs
express
scov
e
protein
pcaggsm
express
scov
protein
pcaggsn
express
scov
n
protein
describ
previous
prepar
mhv
vlp
subconflu
cell
cultur
tissu
cultur
dish
cotransfect
use
reagent
miru
day
posttransfect
cultur
media
collect
centrifug
g
min
filter
total
protein
concentr
vlp
quantit
biorad
dc
protein
assay
accord
manufactur
instruct
biorad
ca
western
blot
perform
describ
previous
detect
mhv
n
protein
use
antimhv
serum
produc
immun
rabbit
purifi
jhm
strain
mhv
kindli
provid
susan
baker
loyola
univers
chicago
detect
scov
protein
mixtur
purifi
rabbit
polyclon
antiscov
protein
antibodi
abgent
cat
polyclon
rabbit
antiscov
protein
antibodi
imgenex
cat
img
use
scov
n
protein
detect
use
rabbit
polyclon
antiscov
n
protein
antibodi
imgenex
cat
img
scov
protein
detect
use
mixtur
scov
pupm
antibodyntermin
abgent
cat
scov
pupm
antibodi
ctermin
abgent
cat
antiscov
antibodi
prosci
cat
cat
wash
gel
water
protein
gel
stain
soak
gel
biosaf
coomassi
stain
biorad
gentl
agit
gel
rins
extens
water
overnight
carbonco
copper
grid
float
drop
chimer
vlp
min
wash
grid
water
three
time
neg
stain
perform
use
phosphotungst
acid
ph
min
air
dri
grid
sampl
examin
philip
transmiss
electron
microscop
pictur
taken
kv
sixto
femal
balbc
mice
charl
river
laboratori
wilmington
hous
cage
cover
barrier
filter
approv
biosafeti
level
anim
facil
maintain
univers
texa
medic
branch
galveston
texa
mous
experi
perform
use
experiment
protocol
approv
univers
texa
medic
branch
investig
anim
care
use
committe
experi
carri
follow
nation
institut
health
unit
state
depart
agricultur
guidelin
mhv
vlp
chimer
vlp
influenza
viru
vaccin
adjust
twice
desir
final
concentr
ml
mix
equal
volum
phosphat
buffer
salin
pb
alum
adjuv
imject
alum
pierc
cat
day
administ
intramuscularli
im
use
tuberculin
syring
normject
tuttingen
germani
bevel
needl
becton
dickinson
cat
control
group
mice
inocul
im
vero
cell
cultur
fluid
mixtur
influenza
vaccin
alum
alum
alon
left
untreat
mice
inocul
day
indic
bodi
paper
second
inject
given
day
experi
scov
inocul
directli
nare
mice
lightli
anesthet
isofluran
isoflo
abbott
laboratori
north
chicago
il
mice
inocul
tcid
scov
day
provid
postinfect
immun
undergo
second
inocul
experi
immun
mice
challeng
intranas
inocul
tcid
scov
day
euthan
day
experi
mice
inocul
scov
day
euthan
day
day
post
inocul
chosen
report
peak
titer
occur
time
confirm
laboratori
mice
anesthet
isofluran
bled
retroorbit
sinu
plexu
heat
inactiv
minut
sera
store
assay
virusspecif
neutral
antibodi
perform
serial
dilut
sampl
serum
begin
dilut
use
fbsdmem
diluent
tissu
cultur
plate
falcon
final
volum
serial
dilut
sampl
well
addit
tcid
scov
well
sampl
incub
min
room
temperatur
mixtur
contain
tcid
scov
transfer
duplic
well
confluent
vero
cell
grown
microtit
plate
h
incub
viru
control
well
exhibit
advanc
virusinduc
cpe
neutral
capac
individu
serum
sampl
assess
determin
presenc
absenc
virusinduc
cpe
scovspecif
neutral
antibodi
titer
express
reciproc
last
dilut
serum
complet
inhibit
virusinduc
cpe
two
day
post
scov
challeng
mice
euthan
lung
remov
lung
lobe
includ
right
middl
lob
right
lower
lob
accessori
lobe
left
lobe
remov
place
buffer
formalin
subsequ
histolog
examin
immunohistochemistri
ihc
describ
previous
viru
titrat
remain
lobe
lung
weigh
frozen
homogen
fb
solut
use
tissuelys
qiagen
retsch
haan
germani
homogen
centrifug
scov
titer
clarifi
fluid
determin
assay
quadrupl
well
vero
cell
plate
titer
viru
lung
homogen
express
tcid
gram
lung
log
minim
detect
level
viru
log
tcid
gram
formalinfix
paraffinembed
tissu
section
subject
standard
hematoxylin
eosin
ihc
stain
evalu
histopatholog
detect
scov
antigen
respect
use
statist
program
instat
version
graphpad
softwar
inc
san
diego
ca
perform
kruskalw
nonparametr
analysi
varianc
anova
test
compar
arithmet
mean
scov
lung
titer
neutral
antibodi
titer
undetect
viru
titer
assign
valu
minim
detect
limit
log
g
lung
undetect
virusspecif
neutral
titer
assign
valu
previous
report
success
product
scov
vlp
cell
cotransfect
four
pcaggsbas
plasmid
encod
scov
n
e
protein
without
use
exogen
virus
protein
express
studi
report
vari
amount
plasmid
cotransfect
abl
gener
approxim
scov
vlp
cell
colloid
coomassi
blue
stain
western
blot
analysi
identifi
scov
n
protein
purifi
scov
vlp
fig
likewis
transfect
four
pcaggsbas
plasmid
encod
mhv
e
n
protein
result
product
mhv
vlp
fig
optim
obtain
approxim
purifi
mhv
vlp
cell
demonstr
effici
mhv
vlp
product
substanti
better
scov
vlp
product
e
protein
drive
vlp
assembl
releas
coronaviru
protein
incorpor
vlp
ms
interact
data
indic
mhv
e
protein
result
effici
vlp
product
scov
e
protein
next
test
whether
coexpress
scov
protein
mhv
e
n
protein
could
result
effici
product
chimer
vlp
would
contain
high
concentr
scov
protein
scov
protein
interact
mhv
protein
robust
vlp
product
machineri
driven
mhv
e
protein
could
result
effici
chimer
vlp
product
chimer
vlp
product
inde
occur
cell
cotransfect
plasmid
express
scov
protein
mhv
n
protein
mhv
protein
mhv
e
protein
fig
colloid
coomassi
blue
stain
western
blot
analysi
purifi
chimer
vlp
show
presenc
scov
mhv
n
mhv
protein
chimer
vlp
low
level
host
protein
contamin
neg
stain
chimer
vlp
reveal
typic
spheric
coronaviru
structur
peplom
fig
optim
approxim
purifi
chimer
vlp
produc
cell
effici
chimer
vlp
product
time
better
scov
vlp
next
test
effici
chimer
vlp
product
vero
cho
cell
use
prepar
human
vaccin
use
variou
dna
transfect
reagent
combin
differ
concentr
plasmid
transfect
effici
chimer
vlp
product
vero
cell
time
lower
cell
data
shown
found
use
product
chimer
vlp
cho
cell
onethird
cell
repeat
experi
data
shown
prolong
incub
transfect
cell
cho
cell
day
posttransfect
improv
accumul
chimer
vlp
supernat
data
shown
assess
use
chimer
vlp
scov
vaccin
candid
first
test
effect
immun
mice
chimer
vlp
serum
neutral
antibodi
product
inhibit
scov
replic
lung
sixto
femal
balbc
mice
inocul
im
mixtur
chimer
vlp
prepar
cell
pb
chimer
vlp
mix
alum
placebo
mice
inocul
im
vero
cell
cultur
fluid
anoth
group
mice
inocul
tcid
scov
produc
solid
postinfect
immun
twentyeight
day
later
mice
bled
determin
serum
neutral
antibodi
titer
fig
subsequ
mice
challeng
tcid
scov
lung
viru
titer
day
post
scov
challeng
determin
fig
scovspecif
neutral
antibodi
detect
sera
mice
inocul
im
placebo
minim
virusspecif
neutral
antibodi
evid
mice
inocul
chimer
vlp
mix
pb
mean
titer
mean
serum
neutral
titer
group
mice
inocul
live
viru
chimer
vlp
administ
alum
statist
differ
statist
significantli
higher
p
mice
immun
mixtur
chimer
vlp
pb
placebo
group
challeng
mice
immun
vero
cell
cultur
fluid
placebo
mixtur
chimer
vlp
pb
high
mean
viru
titer
log
lung
log
lung
respect
contrast
viru
detect
lung
mice
previous
administ
either
live
scov
chimer
vlp
mix
alum
scov
titer
lung
mice
two
day
post
viru
challeng
invers
proport
serum
virusneutr
antibodi
titer
studi
immunogen
chimer
vlp
three
group
mice
inocul
im
mix
alum
group
mice
receiv
mixtur
chimer
vlp
pb
mhv
vlp
alum
influenza
viru
vaccin
alum
vero
cell
cultur
fluid
live
scov
alum
alon
mice
receiv
treatment
mean
neutral
titer
day
post
inocul
mice
receiv
chimer
vlp
alum
respect
fig
absenc
alum
chimer
vlp
induc
lower
signific
neutral
antibodi
respons
mice
infect
scov
neutral
titer
mice
inocul
mhv
vlp
detect
virusspecif
neutral
antibodi
demonstr
mhv
protein
elicit
neutral
antibodi
scov
neutral
antibodi
titer
day
post
inocul
investig
group
mice
inocul
influenza
vaccin
alum
alum
alon
receiv
treatment
day
mice
except
untreat
inocul
live
scov
boost
materi
neutral
antibodi
titer
day
determin
fig
mice
inject
chimer
vlp
alum
increas
titer
lowest
dose
dose
result
mark
booster
respons
anim
receiv
highest
dose
develop
titer
infect
scov
neutral
titer
second
inocul
mixtur
chimer
vlp
pb
effici
boost
median
neutral
antibodi
titer
higher
titer
follow
chimer
vlp
mix
alum
neutral
antibodi
detect
lowest
dilut
test
group
receiv
mhv
vlp
influenza
vaccin
alum
alum
alon
placebo
left
untreat
mice
challeng
live
scov
day
sacrif
two
day
later
expect
maxim
pulmonari
viru
titer
detect
group
mice
inocul
placebo
log
mhv
vlp
log
influenza
vaccin
alum
alum
alon
left
untreat
fig
partial
protect
obtain
group
mice
inocul
twice
chimer
vlp
mix
alum
log
chimer
vlp
pb
log
chimer
vlp
mix
alum
log
notabl
viru
detect
lung
mice
given
live
viru
two
dose
chimer
vlp
mix
alum
mean
lung
viru
titer
latter
two
group
statist
differ
mean
pulmonari
scov
titer
seen
placebo
control
group
mean
compar
use
nonparametr
anova
test
p
valu
overal
viru
level
anim
gener
correl
invers
scovspecif
neutral
antibodi
present
sera
mice
histopatholog
examin
group
mice
neither
produc
neutral
antibodi
suppress
scov
replic
lung
ie
mice
treat
vero
cell
cultur
fluid
inocul
mixtur
influenza
viru
vaccin
alum
alum
alon
well
left
untreat
reveal
moder
interstiti
pneumonia
fig
b
bronchial
epithelium
appear
main
affect
target
promin
cellular
cytoplasm
swell
bleb
extens
accumul
cellular
debri
necrot
epitheli
cell
accompani
inflammatori
infiltr
occur
bronchiol
fig
also
observ
moder
infiltr
mononuclear
cell
around
peribronchiolar
perivascular
region
infect
tissu
mildtomoder
thicken
bronchiolar
interstiti
tissu
alveolar
wall
mononuclear
cell
infiltr
fig
ihc
stain
demonstr
presenc
scov
n
protein
within
bronchiolar
epitheli
cell
within
cell
alveolar
line
fig
contrast
promin
patholog
viral
replic
lung
control
anim
mild
interstiti
pneumonia
found
upon
viral
challeng
mice
previous
immun
mixtur
either
chimer
vlp
pb
chimer
vlp
alum
infect
live
scov
fig
e
g
h
specif
cytopatholog
ie
swell
bleb
rare
observ
bronchiolar
epitheli
cell
despit
presenc
desquam
cell
within
airway
lumen
addit
thicken
bronchiolar
interstiti
tissu
alveolar
wall
cellular
infiltr
less
promin
compar
control
group
big
differ
lung
patholog
mice
inocul
vlp
pb
inocul
vlp
alum
notic
inflammatori
mononuclear
cell
seem
main
cellular
compon
cellular
infiltr
around
peribronchiolar
perivascular
region
mice
initi
prime
live
scov
addit
inflammatori
mononuclear
cell
observ
infiltr
neutrophil
eosinophil
around
bronchiol
blood
vessel
mice
inocul
mixtur
chimer
vlp
pb
chimer
vlp
alum
fig
e
count
infiltr
cell
five
field
mous
lung
tissu
reveal
infiltr
eosinophil
repres
infiltr
cell
mice
inocul
mixtur
chimer
vlp
pb
inocul
chimer
vlp
alum
respect
contrast
infiltr
eosinophil
repres
mere
infiltr
cell
mice
inocul
respect
vero
cell
cultur
fluid
mixtur
influenza
viru
vaccin
alum
alum
alon
left
untreat
present
studi
test
efficaci
immun
mice
chimer
vlp
elicit
antiscovneutr
antibodi
suppress
scov
replic
lung
scovmedi
lung
cytopatholog
although
variou
strategi
scov
vaccin
includ
express
scov
protein
virus
inactiv
scov
particl
dna
vaccin
recombin
protein
approach
report
knowledg
first
report
test
vlp
propag
mammalian
cell
scov
vaccin
candid
appear
chimer
vlp
produc
mammalian
cell
studi
immunogen
scov
vlp
produc
use
baculovirusexpress
system
immun
mice
four
time
baculovirusderiv
scov
vlp
immun
elicit
neutral
antibodi
titer
longer
higher
obtain
present
studi
use
inactiv
scov
scov
vaccin
similar
vaccin
strategi
explor
present
studi
other
report
immun
mice
twice
doubleinactiv
scov
alum
elicit
high
titer
neutral
antibodi
major
neg
aspect
use
inactiv
scov
vaccin
extrem
care
must
taken
complet
inactiv
infecti
scov
vaccin
prepar
contrast
vlpbase
vaccin
strategi
elimin
safeti
concern
accumul
data
suggest
import
compat
protein
endodomain
cytoplasm
tail
protein
assembl
protein
coronaviru
vlp
past
report
protein
assembl
occur
two
region
deriv
viru
differ
coronavirus
accordingli
surpris
find
effici
product
chimer
vlp
carri
scov
protein
mhvderiv
n
e
protein
present
data
suggest
endodomain
scov
protein
interact
effici
mhv
protein
assembl
vlp
endodomain
coronaviru
protein
two
partial
overlap
subregion
ntermin
cysteinerich
region
ctermin
chargerich
region
fig
mhv
lack
ctermin
segment
protein
endodomain
viabl
replic
well
cell
cultur
suggest
remov
carboxytermin
residu
inhibit
interact
mutant
protein
protein
contrast
replic
sever
impair
mhv
mutant
lack
ctermin
amino
acid
amino
acid
protein
endodomain
ie
constitut
major
chargerich
region
furthermor
singl
point
mutat
charg
amino
acid
alanin
chargerich
region
endodomain
detect
effect
incorpor
heterolog
protein
contain
mhv
endodomain
virion
wherea
mutant
contain
multipl
charg
residuestoalanin
significantli
reduc
incorpor
protein
virion
data
suggest
chargerich
region
endodomain
play
key
role
select
inclus
protein
virion
note
charg
residu
transmembran
domain
ctermin
amino
acid
scov
mhv
charg
residu
found
felin
infecti
periton
viru
fipv
fig
fipv
protein
assembl
vlp
virus
carri
mhv
n
e
protein
accordingli
presenc
number
charg
residu
region
endodomain
consid
import
protein
assembl
viru
particl
scov
mhv
impli
virus
similar
structur
portion
endodomain
allow
interact
mhv
protein
inocul
mice
mixtur
chimer
vlp
alum
mhv
vlp
alum
induc
antibodi
neutral
scov
fig
lack
heterolog
protect
confirm
scov
protein
relev
constitu
chimer
vlp
observ
vlp
system
particl
immunogen
inject
provid
protect
challeng
carri
second
im
inject
addit
alum
adjuv
enhanc
induct
neutral
antibodi
inde
titer
reach
postinfect
two
inject
vlp
group
signific
protect
evidenc
reduct
lung
viral
titer
day
virul
viru
challeng
optimum
time
detect
replic
balbc
mous
higher
neutral
antibodi
titer
correl
lower
viru
content
plu
alum
group
detect
viru
overal
data
agreement
past
report
reveal
import
scovspecif
neutral
antibodi
recogn
protein
curb
scov
replic
lung
immun
mice
venezuelan
equin
enceph
viru
replicon
particl
encod
scov
n
protein
induc
enhanc
immunopatholog
includ
infiltr
eosinophil
lung
follow
scov
challeng
impli
possibl
scov
vaccin
lack
n
protein
express
may
desir
would
reduc
potenti
risk
immunopatholog
chang
prime
immun
regard
chimer
vlp
carri
mhv
n
protein
lack
n
protein
unpublish
data
could
elimin
possibl
induct
scov
n
proteininduc
immunopatholog
effici
product
chimer
vlp
cho
cell
report
studi
promis
new
strategi
prepar
vlpbase
scov
vaccin
mammalian
cell
suitabl
prepar
larg
quantiti
vlpbase
vaccin
scov
remain
determin
improv
chimer
vlp
product
eg
codonoptim
scov
gene
mhv
n
e
gene
express
plasmid
develop
inexpens
transfect
reagent
andor
procedur
would
requir
substanti
enhanc
chimer
vlp
product
accumul
data
suggest
antibodi
fipv
protein
fail
protect
cat
fipv
challeng
enhanc
viru
replic
host
antibodydepend
enhanc
ade
report
antibodi
neutral
human
scov
isol
enhanc
entri
scov
isol
civet
cell
cultur
level
unclear
whether
ade
occur
anim
immun
scov
vaccin
candid
observ
sign
ade
studi
mice
immun
chimer
vlp
initi
inocul
scov
effici
suppress
challeng
scov
replic
protein
chimer
vlp
deriv
scov
urbani
strain
also
use
challeng
viru
vlp
induc
antibodi
readili
neutral
scov
vitro
regard
worth
note
immun
mice
venezuelan
equin
enceph
viru
replicon
carri
protein
urbani
strain
show
limit
protect
heterolog
scov
contain
gene
human
isol
subbarao
et
al
report
mild
focal
peribronchiolar
mononuclear
inflammatori
infiltr
scov
antigen
bronchiolar
epitheli
cell
lung
balbc
mice
two
day
post
scov
inocul
stain
scov
monoclon
antibodi
n
protein
also
found
scov
antigen
within
bronchiolar
epitheli
cell
challeng
unimmun
mice
consist
scov
titer
lung
viral
antigen
detect
lung
mice
inocul
chimer
vlp
absenc
scov
antigen
lung
vlpimmun
mice
mice
preexpos
live
viru
indic
result
ihc
stain
fig
strongli
argu
efficaci
chimer
vlp
protect
sarscov
infect
scovinduc
histopatholog
chang
detect
unimmun
mice
studi
appear
similar
slightli
sever
especi
respect
chang
bronchiol
describ
report
subbarao
et
al
scov
challeng
mice
immun
chimer
vlp
show
mix
peribronchiolar
inflammatori
infiltr
slight
thicken
peribronchiolar
interstitium
alveolar
wall
lesion
immun
mice
milder
seen
unimmun
mice
demonstr
effect
chimer
vlp
immun
suppress
scovinduc
cytopatholog
chang
lung
mice
immun
mixtur
chimer
vlp
alum
higher
neutral
antibodi
titer
immun
mixtur
chimer
vlp
pb
group
mice
show
similar
level
scovinduc
lung
cytopatholog
suggest
neither
alum
neutral
antibodi
titer
sole
determin
sever
inflammatori
respons
possibl
cellular
immun
respons
chimer
vlp
protein
suggest
observ
mice
inocul
mixtur
chimer
vlp
pb
chimer
vlp
alum
group
mice
show
infiltr
neutrophil
eosinophil
around
bronchiol
blood
vessel
contrast
report
immun
mice
mixtur
inactiv
scov
adjuv
primari
elicit
humor
immun
respons
investig
use
balbc
mice
also
scov
suscept
mice
anim
model
necessari
evalu
implic
impact
cellular
immun
activ
includ
pulmonari
infiltr
neutrophil
eosinophil
well
util
chimer
vlp
scov
vaccin
scovspecif
neutral
antibodi
titer
immun
mice
day
immun
scov
titer
lung
mice
two
day
intranas
challeng
tcid
scov
day
b
mean
scovspecif
neutral
antibodi
titer
mice
day
inocul
scov
im
inocul
placebo
medium
vero
cell
chimer
vlp
suspend
pb
alum
shown
length
bar
indic
mean
virusspecif
serum
neutral
antibodi
titer
vertic
dash
line
demark
minim
antibodi
detect
level
assay
ie
b
mice
independ
inocul
im
placebo
medium
vero
cell
mixtur
chimer
vlp
pb
mixtur
chimer
vlp
alum
tcid
infecti
scov
day
mice
challeng
tcid
scov
two
day
later
mice
sacrif
viru
titer
lung
determin
shown
graph
length
bar
indic
mean
pulmonari
viru
titer
indic
group
scovspecif
neutral
serum
antibodi
titer
immun
mice
scov
titer
lung
mice
two
day
intranas
challeng
scov
day
day
mice
either
left
untreat
inocul
tcid
scov
inject
im
placebo
medium
vero
cell
mixtur
mhv
vlp
pb
mixtur
chimer
vlp
pb
mixtur
chimer
vlp
alum
mixtur
chimer
vlp
alum
mixtur
chimer
vlp
alum
mixtur
influenza
viru
vaccin
alum
alum
alon
graph
repres
virusspecif
serum
neutral
antibodi
titer
day
post
inocul
number
animalsgroup
lung
histopatholog
immunohistochemistri
control
placebo
immun
mice
day
post
scov
challeng
mice
n
group
inocul
cell
cultur
fluid
twice
day
c
immun
mixtur
chimer
vlp
pb
day
g
chimer
vlp
alum
e
h
day
live
scov
day
f
mice
challeng
scov
day
sacrif
day
bronchiolar
epitheli
cell
show
swell
bleb
lumin
cytoplasm
extens
cellular
debri
compris
necrot
epithelium
inflammatori
cell
airway
lumen
moder
peribronchiolar
mononuclear
inflammatori
cell
infiltr
also
present
hematoxylin
eosin
stain
magnif
b
thicken
bronchiolar
interstiti
tissu
alveolar
wall
mononuclear
cell
infiltr
magnif
c
scov
n
antigen
distribut
bronchiolar
epitheli
cell
determin
immunohistochemistri
magnif
f
bronchiolar
epitheli
cell
show
rare
swell
bleb
lumin
cytoplasm
rare
presenc
cellular
debri
airway
magnif
peribronchiolar
mononuclear
neutrophil
eosinophil
infiltr
inset
magnif
g
scov
antigen
detect
immunohistochemistri
lung
mice
magnif
amino
acid
sequenc
endodomain
scov
mhv
fipv
clustalw
align
carboxyterminu
protein
sequenc
scov
strain
urbani
genbank
access
mhv
strain
genbank
access
fipv
genbank
access
transmembran
domain
cytoplasm
domain
cysteinrich
region
chargerich
region
indic
chargeresidu
membran
proxim
region
shade
twelv
residu
near
c
termin
region
box
asterisk
repres
ident
residu
